Literature DB >> 8987089

Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides?

M D Johnson1, B D Anderson.   

Abstract

PURPOSE: The specific activities of the purine and pyrimidine metabolizing enzymes, purine nucleoside phosphorylase (PNP), adenosine deaminase (ADA) and cytidine deaminase (CDA) were determined in bovine brain microvessel endothelial cells (BBMECs), whole cerebral tissue and erythrocytes. In addition, the substrate specificities (Km and Vmax) of purified calf spleen PNP for inosine and 2',3'-dideoxyinosine (ddI) and of purified calf intestinal ADA for 2',3'-dideoxyadenosine (ddA), 6-chloro-2',3'-dideoxypurine (6-Cl-ddP), and 2'-beta-fluoro-2', 3'-dideoxyadenosine (F-ddA) have been explored.
METHODS: BBMECs were isolated from bovine cerebral cortex by a two step enzymatic dispersion treatment followed by centrifugation over 50% Percoll density gradients. Activities of alkaline phosphatase, gamma-glutamyl transpeptidase, ADA, PNP and CDA were determined in various tissue homogenates (cerebral cortex, BBMECs and erythrocytes). Enzyme kinetic studies were also conducted using commercially available enzymes and several nucleoside analogs of interest.
RESULTS: The activities of ADA and PNP were 42-fold and 247-fold higher in the cerebral microvessels than in the cerebral cortex, respectively, while there was no detectable CDA activity in the microvessel fraction and very little overall activity in the cortex.
CONCLUSIONS: ADA and PNP may serve as an enzymatic blood-brain barrier for some of the anti-HIV dideoxynucleosides. Simulations of brain availability for ddI, ddA, 6-Cl-ddP, and F-ddA demonstrated that the quantitative significance of enzyme localization may vary dramatically, however, depending on the membrane permeability of the drug and its bioconversion rate constant within the endothelial cell.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8987089     DOI: 10.1023/a:1016001712524

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  A STUDY OF THE TISSUE DISTRIBUTION OF ADENOSINE DEAMINASE IN SIX MAMMAL SPECIES.

Authors:  T G BRADY; C I O'DONOVAN
Journal:  Comp Biochem Physiol       Date:  1965-01

2.  Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.

Authors:  J J Barchi; V E Marquez; J S Driscoll; H Ford; H Mitsuya; T Shirasaka; S Aoki; J A Kelley
Journal:  J Med Chem       Date:  1991-05       Impact factor: 7.446

3.  Isolation of metabolically active capillaries from rat brain.

Authors:  G W Goldstein; J S Wolinsky; J Csejtey; I Diamond
Journal:  J Neurochem       Date:  1975-11       Impact factor: 5.372

Review 4.  Drug metabolizing enzymes in the brain and cerebral microvessels.

Authors:  A Minn; J F Ghersi-Egea; R Perrin; B Leininger; G Siest
Journal:  Brain Res Brain Res Rev       Date:  1991 Jan-Apr

5.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

Authors:  F M Balis; P A Pizzo; K M Butler; M E Hawkins; P Brouwers; R N Husson; F Jacobsen; S M Blaney; J Gress; P Jarosinski
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

6.  Drug entry into the brain.

Authors:  S I Rapoport; K Ohno; K D Pettigrew
Journal:  Brain Res       Date:  1979-08-24       Impact factor: 3.252

7.  Deoxycytidylate deaminase and deoxycytidine deaminase in normal and neoplastic human tissues.

Authors:  G Giusti; C Mangoni; B De Petrocellis; E Scarano
Journal:  Enzymol Biol Clin (Basel)       Date:  1970

8.  Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs.

Authors:  J F Ghersi-Egea; B Leninger-Muller; G Suleman; G Siest; A Minn
Journal:  J Neurochem       Date:  1994-03       Impact factor: 5.372

Review 9.  Brain metabolism: a perspective from the blood-brain barrier.

Authors:  W M Pardridge
Journal:  Physiol Rev       Date:  1983-10       Impact factor: 37.312

10.  Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse.

Authors:  D H Ho; C Pincus; C J Carter; R S Benjamin; E J Freireich; G P Bodey
Journal:  Cancer Treat Rep       Date:  1980 Apr-May
View more
  3 in total

Review 1.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

2.  Enhanced oral bioavailability of 2'- beta-fluoro-2',3'-dideoxyadenosine (F-ddA) through local inhibition of intestinal adenosine deaminase.

Authors:  R T DeGraw; B D Anderson
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

3.  Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.

Authors:  D Singhal; M E Morgan; B D Anderson
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.